JLE

Epileptic Disorders

MENU

Vortioxetine suppresses epileptiform activity and cognition deficits in a chronic PTZ-induced kindling rat model Volume 23, numéro 6, December 2021

  • [1] Trinka E., Cock H., Hesdorffer D., Rossetti A.O., Svheffer I.E., Shinnar S. A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56:1515-1523. 10
  • [2] Vezzani A., Friedman A., Dingledine R.J. The role of inflammation in epileptogenesis. Neuropharmacology. 2013;69:16-24.
  • [3] Duncan J.S., Sander J.W., Sisodiya S.M., Walker M.C. Adult epilepsy. Lancet. 2006;367:1087-1100. 9516
  • [4] Bonnycastle D.D., Giarman N.J., Paasonen M.K. Anticonvulsant compounds and 5-hydroxytryptamine in rat brain. Br J Pharmacol Chemother. 1957;12:228-231. 2
  • [5] Prendiville S., Gale K. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia. 1993;34:381-384. 2
  • [6] Statnick M.A., Maring-Smith M.L., Clough R.W., Wang C., Dailey J.W., Jobe P.C. Effect of 5,7-dihydroxytryptamine on audiogenic seizures in genetically epilepsy-prone rats. Life Sci. 1996;59:1763-1771. 21
  • [7] Hernandez E.J., Williams P.A., Dudek F.E. Effects of fluoxetine and TFMPP on spontaneous seizures in rats with pilocarpine-induced epilepsy. Epilepsia. 2002;43:1337-1345. 11
  • [8] Bagdy G., Kecskemeti V., Riba P., Jakus R. Serotonin and epilepsy. J Neurochem. 2007;100:857-873. 4
  • [9] Shiha A.A., de Cristobal J., Delgado M., de la Rosa R.F., Bascunana P., Pozo M.A. Subacute administration of fluoxetine prevents short-term brain hypometabolism and reduces brain damage markers induced by the lithium-pilocarpine model of epilepsy in rats. Brain Res Bull. 2015;111:36-47.
  • [10] Wenger G.R., Stitzel R.E., Craig C.R. The role of biogenic amines in the reserpine-induced alteration of minimal electroshock seizure thresholds in the mouse. Neuropharmacology. 1973;12:693-703. 7
  • [11] Lazarova M., Bendotti C., Samanin R. Studies on the role of serotonin in different regions of the rat central nervous system of pentylenetetrazol-induced seizures and the effect of di-n-propylacetate. Naunyn Schmiedebergs Arch Pharmacol. 1983;322:147-152. 2
  • [12] Tripathi P.P., Di Giovannantonio L., Viegi A., Wurst W., Simeone A., Bozzi Y. Serotonin hyperinnervation abolishes seizure susceptibility in Otx2 conditional mutant mice. J Neurosci. 2008;28:9271-9276. 37
  • [13] Taskiran M. Serotonin and role in epilepsy. J Health Sci. 2019;28:182-187. 3
  • [14] Tecott L.H., Sun L.M., Akana S.F., Strack A.M., Lowenstein D.H., Dallman M.F. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature. 1995;374:542-546. 6522
  • [15] Taskiran M., Tasdemir A., Ayyildiz N., Ayyildiz M., Agar E. The effect of serotonin on penicillin-induced epileptiform activity. Int J Neurosci. 2019;129:687-697. 7
  • [16] Zhao H., Lin Y., Chen S., Li X., Huo H. 5-HT3receptors: a potential therapeutic target for epilepsy. Curr Neuropharmacol. 2018;16:29-36. 1
  • [17] Aithal S., Balaji V., Geeta S., Swetha E.S., Udupa A.L. Anticonvulsant activity of Granisetron in Albino mice. Int J Pharmacol Res. 2015;5:119-121. 5
  • [18] Gokul C.G., Halemani S.S., Acharya A., Santhosh, Adake P. Evaluation of antiepileptic activity of Ondansetron in Albino Rats. Pharma Innov J. 2017;6:112-118.
  • [19] Yang Z., Liu X., Yin Y., Sun S., Deng X. Involvement of 5-HT(7) receptors in the pathogenesis of temporal lobe epilepsy. Eur J Pharmacol. 2012;685:52-58. 1-3
  • [20] Stahl S.M. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr. 2015;20:331-336. 4
  • [21] D’Agostino A., English C.D., Rey J.A. Vortioxetine (brintellix): a new serotonergic antidepressant. P T. 2015;40:36-40. 1
  • [22] Ögün M.N., Çetinkaya A., Beyazçiçek E. The effect of vortioxetine on penicillin-induced epileptiform activity in rats. Arq Neuropsiquiatr. 2019;77:412-417. 6
  • [23] Fischer W., Kittner H. Influence of ethanol on the pentylenetetrazol-induced kindling in rats. J Neural Transm. 1998;105:1129-1142. 10
  • [24] Gorska N., Slupski J., Cubala W.J. Antipsychotic drugs in epilepsy. Neurol Neurochir Pol. 2019;53:408-412. 6
  • [25] Etemad L., Zamani M., Iranshahi M., Roohbakhsh A. The protective effect of auraptene against oxidative stress and pentylenetetrazol-induced chemical kindling in mice. Iran J Pharm Res. 2019;18:1395-1402. 3
  • [26] Tahmasebi S., Oryan S., Mohajerani H.R., Akbari N., Palizvan M.R. Probiotics and Nigella sativa extract supplementation improved behavioral and electrophysiological effects of PTZ-induced chemical kindling in rats. Epilepsy Behav. 2020;104:106897. Pt A
  • [27] Günaydın C., Arslan G., Bilge S.S. Proconvulsant effect of trans-cinnamaldehyde in pentylenetetrazole-induced kindling model of epilepsy: the role of TRPA1 channels. Neurosci Lett. 2020;721:134823.
  • [28] Górska N., Słupski J., Cubała W.J., Wiglusz M.S., Gałuszko-Węgielnik M. Antidepressants in epilepsy. Neurol Neurochir Pol. 2018;52:657-661. 6
  • [29] Qiu X., Zingano B., He S., Zhu X., Peng A., Duan J. Antiepileptic effect of olanzapine in epilepsy patients with atypical depressive comorbidity. Epileptic Disord. 2018;20:225-231. 3
  • [30] Yan Q.S., Jobe P.C., Cheong J.H., Ko K.H., Dailey J.W. Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol. 1994;350:149-152. 2
  • [31] Aygun H. The effect of fluoxetine on penicillin-induced epileptiform activity. Epilepsy Behav. 2019;95:79-86.
  • [32] Pottoo F.H., Tabassum N., Javed M.N., Nigar S., Rasheed R., Khan A. The synergistic effect of raloxifene, fluoxetine, and bromocriptine protects against pilocarpine-induced status epilepticus and temporal lobe epilepsy. Mol Neurobiol. 2019;56:1233-1247. 2
  • [33] Brennecke A., Weaver D.F. Anticonvulsant effects of sertraline: a case report. Seizure. 2020;80:1-2.
  • [34] Mahableshwarkar A.R., Jacobsen P.L., Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013;29:217-226. versus3
  • [35] Pearson J.N., Schulz K.M., Patel M. Specific alterations in the performance of learning and memory tasks in models of chemoconvulsant-induced status epilepticus. Epilepsy Res. 2014;108:1032-1040. 6
  • [36] McIntyre R.S., Lophaven S., Olsen C.K. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17:1557-1567. 10
  • [37] Bruno A., Zoccali R.A., Troili G.M., Scala L., Pandolfo G., Cedro C. Vortioxetine on cognition in schizophrenia: a pilot study. J Clin Psychopharmacol. 2020;40:381-385. 4
  • [38] Unal G., Taskiran M. Vortioxetine improved social and cognitive deficits in acute ketamine model of schizophrenia in rats. J Res Pharm. 2020;24:648-655. 5